Aspira Women's Health Inc. — Form 8-K/A
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K/A
▼ Likely negative
significance 78/100
What the filing says
Michael Buhle terminated as CEO effective June 17, 2026. Receives $200,000 severance (6 months base salary, paid in installments through 12/2026), 6 months COBRA coverage, and accelerated vesting of 64,583 stock options at $0.07/share exercise price. Of his 375,000 granted options, 35,417 were vested at separation; remaining 339,583 forfeit. Newly vested options subject to 90-day lock-up, $0.45 price floor, 2,500 daily share limit, and broker approval.
Why this rating
CEO departure is material for ~$4.7M company; severance + vesting packages ~$245K total (5%+ of market cap). Leadership void and equity dilution from 64,583 accelerated options represent real trajectory risk.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.